Corcept Therapeutics Incorporated (CORT): Price and Financial Metrics
Corcept Therapeutics Incorporated (CORT)
Today's Latest Price: $17.78 USD
Updated Oct 20 4:00pm
Add CORT to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
CORT Stock Summary
- For CORT, its debt to operating expenses ratio is greater than that reported by just 5.24% of US equities we're observing.
- CORT's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 8.99% of US stocks.
- With a year-over-year growth in debt of 205.31%, Corcept Therapeutics Inc's debt growth rate surpasses 92.46% of about US stocks.
- If you're looking for stocks that are quantitatively similar to Corcept Therapeutics Inc, a group of peers worth examining would be NPTN, NBIX, FLGT, SEDG, and ANET.
- Visit CORT's SEC page to see the company's official filings. To visit the company's web site, go to www.corcept.com.
CORT Stock Price Chart Interactive Chart >
CORT Price/Volume Stats
| Current price | $17.78 | 52-week high | $23.48 |
| Prev. close | $17.70 | 52-week low | $9.70 |
| Day low | $17.66 | Volume | 750,700 |
| Day high | $18.19 | Avg. volume | 1,603,966 |
| 50-day MA | $16.45 | Dividend yield | N/A |
| 200-day MA | $14.43 | Market Cap | 2.05B |
Corcept Therapeutics Incorporated (CORT) Company Bio
Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders. The company was founded in 1998 and is based in Menlo Park, California.
CORT Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $17.78 | $1008.4 | 5597% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Corcept Therapeutics Inc. To summarize, we found that Corcept Therapeutics Inc ranked in the 95th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. In terms of the factors that were most noteworthy in this DCF analysis for CORT, they are:
- The company's balance sheet shows it gets 100% of its capital from equity, and 0% of its capital from debt. Its equity weight surpasses that of 95.31% of free cash flow generating stocks in the Healthcare sector.
- The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately merely 2.31% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- Corcept Therapeutics Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -26.74. This coverage rate is greater than that of merely 4.54% of stocks we're observing for the purpose of forecasting via discounted cash flows.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 5485% |
| 1% | 5541% |
| 2% | 5597% |
| 3% | 5653% |
| 4% | 5709% |
| 5% | 5765% |
Want more companies with a valuation profile/forecast similar to that of Corcept Therapeutics Inc? See BEAT, USNU, AMRX, ACHC, and AMEH.
Loading social stream, please wait...